Innate Pharma EBITDA vs. Gross Profit
| IPHA Stock | USD 1.68 0.12 6.67% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -1.8 M | Current Value -1.9 M | Quarterly Volatility 24.6 M |
For Innate Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Innate Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Innate Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Innate Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Innate Pharma over time as well as its relative position and ranking within its peers.
Innate |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Innate Pharma Gross Profit vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Innate Pharma's current stock value. Our valuation model uses many indicators to compare Innate Pharma value to that of its competitors to determine the firm's financial worth. Innate Pharma is currently regarded as number one stock in ebitda category among its peers. It is rated second overall in gross profit category among its peers . At present, Innate Pharma's EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innate Pharma's earnings, one of the primary drivers of an investment's value.Innate Gross Profit vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Innate Pharma |
| = | (1.84 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Innate Pharma |
| = | 57.67 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Innate Gross Profit Comparison
Innate Pharma is currently under evaluation in gross profit category among its peers.
Innate Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Innate Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Innate Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Innate Pharma's change in net profit over the period of time. It can combine multiple indicators of Innate Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 495 K | 519.8 K | |
| Operating Income | -12.7 M | -13.3 M | |
| Income Before Tax | -7.6 M | -7.9 M | |
| Total Other Income Expense Net | 5.1 M | 5.4 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Income Tax Expense | -9.7 M | -9.2 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Net Loss | -52.3 M | -49.7 M | |
| Net Interest Income | 2.5 M | 2.7 M | |
| Interest Income | 3.2 M | 4.6 M | |
| Change To Netincome | 7 M | 7.3 M | |
| Net Loss | (0.09) | (0.10) | |
| Income Quality | 4.30 | 4.52 | |
| Net Income Per E B T | 1.54 | 0.94 |
Innate Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Innate Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Innate Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Innate Pharma's important profitability drivers and their relationship over time.
Use Innate Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Innate Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will appreciate offsetting losses from the drop in the long position's value.Innate Pharma Pair Trading
Innate Pharma Pair Trading Analysis
The ability to find closely correlated positions to Innate Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Innate Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Innate Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Innate Pharma to buy it.
The correlation of Innate Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Innate Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Innate Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Innate Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Innate Pharma position
In addition to having Innate Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
To fully project Innate Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Innate Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Innate Pharma's income statement, its balance sheet, and the statement of cash flows.